Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice

Journal of Lipid Research

Volumn 39, Issue 5, 1998, Pages 1079-1090

  Bird, David A ^a   Tangirala, Rajendra K ^a   Fruebis, Joachim ^a   Steinberg, Daniel ^a   Witztum, Joseph L ^a   Palinski, Wulf ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Antioxidants; Arteriosclerosis; Mice; Modified lipoproteins; Oxidation

Indexed keywords

ALPHA TOCOPHEROL; LOW DENSITY LIPOPROTEIN; PROBUCOL;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DOSE RESPONSE; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; TREATMENT PLANNING;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, DIETARY; FEMALE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED C57BL; PROBUCOL; RECEPTORS, LDL; VITAMIN E;

EID: 0031899142     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
2. Steinberg, D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272: 20963-20966.
3. Berliner, J. A., M. Navab, A. M. Fogelman, J. S. Frank, L. L. Demer, P. A. Edwards, A. D. Watson, and A. J. Lusis. 1995. Atherosclerosis: Basic mechanisms, oxidation, inflammation, and genetics. Circulation. 91: 2488-2496.
4. Haberland, M. E., D. Fong, and L. Cheng. 1988. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241: 215-218.
5. Palinski, W., M. E. Rosenfeld, S. Ylä-Herttuala, G. C. Gurtner, S. A. Socher, S. Butler, S. Parthasarathy, T. E. Carew, D. Steinberg, and J. L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86: 1372-1376.
6. Ylä-Herttuala, S., W. Palinski, M. E. Rosenfeld, S. Parthasarathy, T. E. Carew, S. Butler, J. L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84: 1086-1095.
7. Boyd, H. C., A. M. Gown, G. Wolfbauer, and A. Chait. 1989. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe Heritable Hyperlipidemic rabbit. Am. J. Pathol. 135: 815-826.
8. Rosenfeld, M. E., W. Palinski, S. Ylä-Herttuala, S. Butler, and J. L. Witztum. 1990. Distribution of oxidation-specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10: 336-349.
9. Hammer, A., G. Kager, G. Dohr, H. Rabl, I. Ghassempur, and G. Jürgens. 1995. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 704-713.
10. Kita, T., Y. Nagano, M. Yokode, K. Ishii, N. Kume, A. Ooshima, H. Yokida, and C. Kawai. 1987. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84: 5928-5931.
11. Carew, T. E., D. C. Schwenke, and D. Steinberg. 1987. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit Proc. Natl. Acad. Sci. USA. 84: 7725-7729.
12. Björkhem, I., A. Henriksson-Freyschuss, O. Breuer, U. Diczfalusy, L. Berglund, and P. Henriksson. 1991. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler. Thromb. 11: 15-22.
13. Sparrow, C. P., T. W. Doebber, J. Olszewski, M. S. Wu, J. Ventre, K. A. Stevens, and Y. S. Chao. 1992. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′′-diphenyl-phenylenediamine. J. Clin. Invest. 89: 1885-1891.
14. Parker, R. A., T. Sabrah, M. Cap, and B. T. Gill. 1995. Relation of vascular oxidative stress, α-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler. Thromb. Vasc. Biol. 15: 349-358.
15. Sasahara, M., E. W. Raines, A. Chait, T. E. Carew, D. Steinberg, P. W. Wahl, and R. Ross. 1994. Inhibition of hypercholesterolemia-induced atherosclerosis in Macaca nemestrina by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J. Clin. Invest. 94: 155-164.
16. Chang, M. Y., M. Sasahara, A. Chait, E. W. Raines, and R. Ross. 1995. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol: II. Cellular composition and proliferation. Arterioscler. Thromb. Vas. Biol. 15: 1631-1640.
17. Akeson, A. L., C. W. Woods, L. B. Mosher, C. E. Thomas, and R. L. Jackson. 1991. Inhibition of IL-1 beta expression in THP-1 cells by probucol and tocopherol. Atherosclerosis. 86: 261-270.
18. Fruebis, J., V. Gonzales, M. Silvestre, and W. Palinski. 1997. Effect of probucol treatment on gene expression of VCAM-1, MCP-1 and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17: 1289-1302.
19. Li, H., M. I. Cybulsky, M. A. Gimbrone, and P. Libby. 1993. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. 13: 197-204.
20. Cybulski, M. I., and M. A. Gimbrone. 1991. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251: 788-791.
21. Fruebis, J., D. A. Bird, J. Pattison, and W. Palinski. 1997. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J. Lipid Res. 38: 2455-2464.
22. Witztum, J. L. 1993. Murine models for study of lipoprotein metabolism and atherosclerosis. J. Clin. Invest. 92: 536-537.
23. Breslow, J. L. 1996. Mouse models of atherosclerosis. Science. 272: 685-688.
24. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setälä, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
25. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471.
26. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893.
27. Reddick, R. L., S. H. Zhang, and N. Maeda. 1994. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14: 141-147.
28. Nakashima, Y., A. S. Plump, E. W. Raynes, J. L. Breslow, and R. Ross. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the aortic tree. Arterioscler. Thromb. 14: 133-140.
29. Palinski, W., V. Old, A. S. Plump, J. L. Breslow, D. Steinberg, and J. L. Witztum. 1994. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high liters of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14: 605-616.
30. Palinski, W., R. K. Tangirala, E. Miller, S. G. Young, and J. L. Witztum. 1995. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15: 1569-1576.
31. Palinski, W., S. Hörkkö, E. Miller, U. P. Steinbrecher, H. C. Powell, L. K. Curtiss, and J. L. Witztum. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apoE-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98: 800-814.
32. Hörkkö, S., E. Miller, E. Dudl, P. D. Reaven, N. J. Zvaifler, R. Terkeltaub, S. S. Pierangeli, L. K. Curtiss, D. W. Branch, W. Palinski, and J. L. Witztum. 1996. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low-density lipoprotein. J. Clin. Invest. 98: 815-825.
33. Tangirala, R. K., F. Casanada, J. L. Witztum, D. Steinberg, and W. Palinski. 1995. Effect of the antioxidant N,N′-diphenyl 1,4-phenylenediamine (DPPD) on atherogenesis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 15: 1625-1630.
34. Zhang, S. H., R. L. Reddick, E. Avdievich, L. K. Surles, R. G. Jones, J. B. Reynolds, S. H. Quarfordt, and N. Maeda. 1997. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99: 2858-2866.
35. Ishibashi, S., J. L. Goldstein, M. S. Brown, J. Herz, and D. K. Burns. 1994. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93: 1885-1893.
36. Siedel, J., E. O. Haegele, J. Ziegenhorn, and A. W. Wahlefeld. 1983. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin. Chem. 29: 1075-1080.
37. Bachorik, P. S., P. D. Wood, J. J. Albers, P. Steiner, M. Dempsey, K. Kuba, R. Warnick, and L. Karlsson. 1976. Plasma high-density lipoprotein cholesterol concentrations determined after removal of other lipoproteins by heparin/manganese precipitation or by ultracentrifugation. Clin. Chem. 22: 1828-1834.
38. Fruebis, J., D. Steinberg, H. A. Dresel, and T. E. Carew. 1994. A comparison of the antiatherogenic effects of probucol and of a structural analog of probucol in low density lipoprotein receptor-deficient rabbits. J. Clin. Invest. 94: 392-398.
39. Tangirala, R. K., E. M. Rubin, and W. Palinski. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apo-protein E-deficient mice. J. Lipid Res. 36: 2320-2328.
40. Hayek, T., T. Chajek-Shaul, A. Walsh, N. Azrolan, and J. L. Breslow. 1991. Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprolein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice. Arterioscler. Thromb. 11: 1295-1302.
41. Witztum, J. L., D. Simmons, D. Steinberg, W. F. Beltz, R. Weinreb, S. G. Young, P. Lester, N. Kelly, and J. Juliano. 1989. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation. 79: 16-28.
42. Reaven, P. D., S. Parthasarathy, W. F. Beltz, and J. L. Witztum. 1992. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler. Thromb. 12: 318-324.
43. 2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler. Thromb. Vasc. Biol. 15: 1049-1056.
44. Schäfer Elinder, L., K. Hådell, J. Johansson, J. Mölgaard, I. Holme, A. G. Olsson, and G. Walldius. 1995. Probucol treatment decreases serum concentrations of diet-derived antioxidants. Arterioscler. Thromb. Vasc. Biol. 15: 1057-1063.
45. Esterbauer, H., H. Puhl, M. Dieber-Rotheneder, G. Waeg, and H. Rabl. 1991. Effect of antioxidants on oxidative modification of LDL. Ann. Med. 23: 573-581.
46. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
47. Paszty, C., N. Maeda, J. Verstuyft, and E. M. Rubin. 1994. Apolipoprotein A-I transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94: 899-903.
48. Plump, A. S., C. J. Scott, and J. L. Breslow. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91: 9607-9611.
49. Libby, P., and Z. S. Galis. 1995. Cytokines regulate genes involved in atherogenesis. Ann. N.Y. Acad. Sci. 748: 158-168.
50. Cushing, S. D., J. A. Berliner, A. J. Valente, M. C. Territo, M. Navab, F. Parhami, R. Gerrity, C. J. Schwartz, and A. M. Fogelman. 1990. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA. 87: 5134-5138.
51. Rajavashisth, T. B., A. Andalibi, M. C. Territo, J. A. Berliner, M. Navab, A. M. Fogelman, and A. J. Lusis. 1990. Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factors by modified low density lipoproteins. Nature. 334: 254-257.
52. Rajavashisth, T. B., H. Yamada, and N. K. Mishra. 1995. Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Involvement of nuclear factor-kappa B. Arterioscler. Thromb. Vasc. Biol. 15: 1591-1598.
53. Liao, F., A. Andalibi, F. C. deBeer, A. M. Fogelman, and A. J. Lusis. 1993. Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J. Clin. Invest. 91: 2572-2579.
54. Liao, F., A. Andalibi, J. H. Qiao, H. Allayee, A. M. Fogelman, and A. J. Lusis. 1994. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin. Invest. 94: 877-884.
55. O'Brien, K., Y. Nagano, A. Gown, T. Kita, and A. Chait. 1991. Probucol treatment affects the cellular composition but not antioxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. 11: 751-759.
56. Crawford, R. S., E. Kirk, M. E. Rosenfeld, R. C. LeBoeuf, and A. Chait. 1997. Inhibition of LDL oxidation and atherogenesis by dietary antioxidants in LDL receptor-null mice. (Abstract). Circulation (Suppl.). 96: I658.